Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan
Authors:
- 1 June 2019
- journal article
- research article
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 25 (6) , 646-651
Abstract
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors have repeatedly shown no reduction in the clinical outcomes of cardiovascular death, myocardial infarction, stroke, or all-cause mortality. Bec...Keywords
This publication has 16 references indexed in Scilit:
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2015
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trialThe Lancet, 2015
- Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and MetforminDiabetes Care, 2013
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Diabetes & Endocrinology, 2013
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesNew England Journal of Medicine, 2013
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trialThe Lancet, 2012
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008